Phenyl-cyanoquinolinone PDE9 inhibitors
AssigneeMerck Sharp & Dohme Corp.
InventorsVictoria Cofre, Antonella Converso, Kevin Rodzinak
Life of this patent
Estimating the term…
Abstract
The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Claims8
A compound of the formula Ia, or a pharmaceutically acceptable salt thereof:
- wherein:
- R6 is methyl or ethyl;
- R5 is hydrogen;
- and
- R7 is hydrogen or fluoro.
A compound which is selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.